{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:00:12Z","timestamp":1787068812587,"version":"build-2736575974"},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Impaired performance on motor tasks in children treated for acute lymphoblastic leukemia (ALL) after completion of treatment is often attributed to vincristine (VCR). Whether motor problems persist in other children who receive different cumulative doses of VCR is to the authors' knowledge not known. The objective of the current study was to determine the extent of motor problems in children with ALL, Wilms tumor (WT), B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL), and malignant mesenchymal tumors (MMT) and whether these motor problems were related to VCR dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>In 128 children ages 4\u201312 years who completed treatment after at least 1 year, motor performance was measured using the Movement Assessment Battery for Children (m\u2010ABC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      The m\u2010ABC scores of the total study group were significantly lower than those of the normal population (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). There were no differences in scores noted between children with ALL, WT, B\u2010NHL, or MMT. There also were no differences noted between those children with ALL who had received pulses of VCR and steroids during maintenance therapy and those who had not. All groups demonstrated large variability in scores. Scores were not found to be significantly different between those children who had received low (&lt; 20 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), intermediate (20\u201340 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), or high (&gt; 40 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) cumulative doses of VCR. Cumulative doses of corticosteroids and methotrexate did not affect scores, nor did age at diagnosis and time since the completion of therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Although motor performance was impaired in all patient groups, no correlation was found between motor performance and the cumulative dose of VCR or other drugs, age, and follow\u2010up time. Future studies have to address several issues, including whether polymorphisms in drug metabolizing genes or drug target genes explain the significant variability noted in the long\u2010term motor outcome of children with cancer. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.21706","type":"journal-article","created":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T18:16:56Z","timestamp":1138817816000},"page":"1395-1401","source":"Crossref","is-referenced-by-count":70,"title":["Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine"],"prefix":"10.1002","volume":"106","author":[{"given":"Annelies","family":"Hartman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor","family":"van den Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Stijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,2]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"44","volume-title":"Cancer in children: clinical management","author":"Riccardi R","year":"1998"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(98)00023-7"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.52.7.525"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442447"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02072486"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199612)27:6<551::AID-MPO8>3.0.CO;2-K"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199904)32:4<279::AID-MPO7>3.0.CO;2-T"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199808)31:2<86::AID-MPO7>3.0.CO;2-V"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910501)67:9<2241::AID-CNCR2820670905>3.0.CO;2-A"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G"},{"key":"e_1_2_5_12_2","first-page":"169","article-title":"Results of the DCLSG\u2010study ALL8 (1991\u20101997): BFM oriented treatment without cranial irradiation (CI) and comparing conventional oral and high\u2010doses intravenous 6\u2010mercaptopurine","volume":"33","author":"Kamps WA","year":"1999","journal-title":"Med Pediatr Oncol."},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.911"},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1200\/JCO.1983.1.10.595","article-title":"SIOP (International Society of Paediatric Oncology) and the management of Wilms' tumor","volume":"1","author":"D'Angio GJ","year":"1983","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0094-0143(05)70092-6"},{"key":"e_1_2_5_16_2","volume-title":"Movement assessment battery for children","author":"Henderson S","year":"1992"},{"key":"e_1_2_5_17_2","volume-title":"Movement assessment battery for children; Nederlandse bewerking","author":"Smits\u2010Engelsman BC","year":"1998"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.2466\/pms.2001.93.1.275"},{"key":"e_1_2_5_19_2","unstructured":"Centraal Bureau Statistiek (Statistics Netherlands). Tourism recreation sports. Available from URL:http:\/\/www.cbs.nl[accessed January 26 2006]."},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0887-8994(95)00191-3"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199502000-00001"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(97)80253-X"},{"key":"e_1_2_5_23_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01241398-200005000-00012","article-title":"Avascular necrosis in children with acute lymphoblastic leukemia","volume":"20","author":"Wei SY","year":"2000","journal-title":"J Pediatr Orthop."},{"key":"e_1_2_5_24_2","first-page":"1050","article-title":"Methotrexate\u2010related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia","volume":"4","author":"Shuper A","year":"2002","journal-title":"Isr Med Assoc J."},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-8994(00)00242-3"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128072-200103040-00001"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.18.3262"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.12.3066"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(94)90027-2"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(85)90057-7"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.115.2.345"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.128.1.139"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10503"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000154642.45474.28"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.81.5.442"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20123"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21706","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:26:26Z","timestamp":1760282786000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,3,15]]}},"alternative-id":["10.1002\/cncr.21706"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21706","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}